Literature DB >> 24915017

Graft survival versus glaucoma treatment after penetrating or Descemet stripping automated endothelial keratoplasty.

Matthew S Ward1, Kenneth M Goins, Mark A Greiner, Anna S Kitzmann, John E Sutphin, Wallace L M Alward, Emily C Greenlee, Young H Kwon, M Bridget Zimmerman, Michael D Wagoner.   

Abstract

PURPOSE: The aim of this study was to assess and compare the association of glaucoma therapy with graft survival after performing penetrating keratoplasty (PKP) and Descemet stripping automated endothelial keratoplasty (DSAEK).
METHODS: A retrospective chart review was performed of cases: primary PKP from January 1, 2003, to December 31, 2005, or primary DSAEK from January 1, 2006, to December 31, 2008. Eyes with a surgical indication of pseudophakic corneal edema were included in the statistical analysis. Eyes were stratified by glaucoma treatment into those with (1) no glaucoma treatment, (2) medical therapy only, or (3) surgical intervention. The main outcome measure was graft survival.
RESULTS: Fifty-seven PKP-operated and 156 DSAEK-operated eyes met the inclusion criteria. After PKP and DSAEK, respectively, the 5-year Kaplan-Meier graft survival was 94.7% and 93.8% in eyes with no glaucoma treatment (P > 0.99), 93.8% and 96.3% in eyes with medical therapy only (P > 0.99), and 56.8% and 50% in eyes with surgical intervention (P > 0.99). After both procedures were performed, graft survival was significantly worse in eyes with surgical intervention compared with that in eyes with no glaucoma treatment (P < 0.0001) or in eyes with medical therapy alone (P < 0.0001).
CONCLUSIONS: PKP and DSAEK have comparable graft survival in eyes without glaucoma management and in those with comparable glaucoma management.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24915017     DOI: 10.1097/ICO.0000000000000170

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  7 in total

1.  Boston type 1 keratoprosthesis for failed keratoplasty.

Authors:  Jonathan L Hager; David L Phillips; Kenneth M Goins; Anna S Kitzmann; Mark A Greiner; Alex W Cohen; Jeffrey D Welder; Michael D Wagoner
Journal:  Int Ophthalmol       Date:  2015-05-16       Impact factor: 2.031

2.  Descemet membrane endothelial keratoplasty (DMEK) early stage graft failure in eyes with preexisting glaucoma.

Authors:  Maximilian Treder; Maged Alnawaiseh; Nicole Eter
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-04-08       Impact factor: 3.117

3.  Feeder-free differentiation of cells exhibiting characteristics of corneal endothelium from human induced pluripotent stem cells.

Authors:  Michael D Wagoner; Laura R Bohrer; Benjamin T Aldrich; Mark A Greiner; Robert F Mullins; Kristan S Worthington; Budd A Tucker; Luke A Wiley
Journal:  Biol Open       Date:  2018-05-08       Impact factor: 2.422

4.  Corneal endothelial cell density loss following glaucoma surgery alone or in combination with cataract surgery: a systematic review protocol.

Authors:  Clarissa E H Fang; Peng Tee Khaw; Rashmi G Mathew; Christin Henein
Journal:  BMJ Open       Date:  2021-09-13       Impact factor: 2.692

5.  Comparison of long-term outcomes of trabeculectomy and risk factors for failure in eyes post penetrating keratoplasty or Descemet's stripping endothelial keratoplasty.

Authors:  S Ramyashri; Ashik Mohamed; Sunita Chaurasia; Sirisha Senthil
Journal:  Indian J Ophthalmol       Date:  2022-03       Impact factor: 2.969

6.  Distinctive and pervasive alterations in aqueous humor protein composition following different types of glaucoma surgery.

Authors:  Cyril Rosenfeld; Marianne O Price; Xianyin Lai; Frank A Witzmann; Francis W Price
Journal:  Mol Vis       Date:  2015-08-25       Impact factor: 2.367

7.  Outcomes of complex Descemet Stripping Endothelial Keratoplasty performed by cornea fellows.

Authors:  Jacquelyn Daubert; Terrence P O'Brien; Eldad Adler; Oriel Spierer
Journal:  BMC Ophthalmol       Date:  2018-10-30       Impact factor: 2.209

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.